In the phase III LYM-3002 trial, patients with untreated stage II–IV mantle cell lymphoma were randomly assigned to receive either rituximab, cyclophosphamide, doxorubicin, bortezomib, and prednisone (VR-CAP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). In an 82-month follow-up analysis of 140 patients in the VR-CAP group and 128 patients in the R-CHOP group, median overall survival was significantly longer in the VR-CAP group (90.7 months versus 55.7 months; P = 0.001). The toxicity profile of both regimens was considered manageable: discontinuation owing to treatment-related adverse events (AEs) occurred in 8% of patients in the VR-CAP group and 6% of the R-CHOP group; 4% of patients in each group died owing to treatment-related AEs.
References
Original article
Robak, T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30685-5 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Benefit with VR-CAP in mantle cell lymphoma. Nat Rev Clin Oncol 16, 6 (2019). https://doi.org/10.1038/s41571-018-0130-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0130-z